JP2022541322A - ２型真性糖尿病及び中等度の腎障害を有する患者の治療に対するソタグリフロジンの使用 - Google Patents

２型真性糖尿病及び中等度の腎障害を有する患者の治療に対するソタグリフロジンの使用 Download PDF

Info

Publication number
JP2022541322A
JP2022541322A JP2022504622A JP2022504622A JP2022541322A JP 2022541322 A JP2022541322 A JP 2022541322A JP 2022504622 A JP2022504622 A JP 2022504622A JP 2022504622 A JP2022504622 A JP 2022504622A JP 2022541322 A JP2022541322 A JP 2022541322A
Authority
JP
Japan
Prior art keywords
sotagliflozin
dose
type
diabetes
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022504622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541322A5 (enExample
Inventor
デイヴィッド ブレグマン
アリ ハリリ
Original Assignee
レクシコン ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レクシコン ファーマシューティカルズ インコーポレイテッド filed Critical レクシコン ファーマシューティカルズ インコーポレイテッド
Publication of JP2022541322A publication Critical patent/JP2022541322A/ja
Publication of JP2022541322A5 publication Critical patent/JP2022541322A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022504622A 2019-07-25 2020-07-24 ２型真性糖尿病及び中等度の腎障害を有する患者の治療に対するソタグリフロジンの使用 Pending JP2022541322A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188477.4A EP3769767A1 (en) 2019-07-25 2019-07-25 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
EP19188477.4 2019-07-25
PCT/IB2020/057016 WO2021014420A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Publications (2)

Publication Number Publication Date
JP2022541322A true JP2022541322A (ja) 2022-09-22
JP2022541322A5 JP2022541322A5 (enExample) 2023-08-01

Family

ID=67438963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022504622A Pending JP2022541322A (ja) 2019-07-25 2020-07-24 ２型真性糖尿病及び中等度の腎障害を有する患者の治療に対するソタグリフロジンの使用

Country Status (7)

Country Link
US (1) US20220265690A1 (enExample)
EP (2) EP3769767A1 (enExample)
JP (1) JP2022541322A (enExample)
CN (1) CN114222571A (enExample)
AU (1) AU2020319164A1 (enExample)
CA (1) CA3148400A1 (enExample)
WO (1) WO2021014420A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010959A2 (en) 2006-07-14 2008-01-24 The Trustees Of The University Of Pennsylvania Beam ablation lithography

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 92, no. 2, JPN6024031237, 2012, pages 158 - 169, ISSN: 0005519644 *
CLINICAL THERAPEUTICS, vol. 37, no. 1, JPN6024031236, 2015, pages 71 - 82, ISSN: 0005519643 *

Also Published As

Publication number Publication date
CA3148400A1 (en) 2021-01-28
CN114222571A (zh) 2022-03-22
WO2021014420A1 (en) 2021-01-28
EP4003366A1 (en) 2022-06-01
US20220265690A1 (en) 2022-08-25
EP3769767A1 (en) 2021-01-27
AU2020319164A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
Cherney et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Kovacs et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus
Lehrke et al. Safety and tolerability of linagliptin in patients with type 2 diabetes: a comprehensive pooled analysis of 22 placebo-controlled studies
EP2771024B1 (en) Treatment protocol of diabetes type 2
AU2012229330B2 (en) Dosing regimens for the treatment of Fabry disease
JP2015164964A5 (enExample)
JP2013536255A (ja) ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
CN116867505A (zh) 替西帕肽治疗方法
AU2020206021B2 (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
CN114286682A (zh) 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
EP2575826B1 (en) Anti-diabetic compositions
JP7482146B2 (ja) １型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用
KR20230143978A (ko) 시클로-히스프로를 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 제제
WO2021014420A1 (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
HK40062957A (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
CN102068441A (zh) 一种含有替米沙坦和格列美脲的复方制剂
Gupta 25 Intensive Glycemic Control: Is it
HK40051480A (en) Use of sotagliflozin for the treatment of patients with type 1 diabetes mellitus
HK40036814A (en) Dosing regimens for the treatment of fabry disease
de Souza Faustino et al. The Benefits of SGLT2 Inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
JP2011105609A (ja) メトホルミンへの付加療法を含む２型糖尿病の治療方法
Jeon Rhabdomyolysis: case report
Elliott et al. Empagliflozin Tablets (Jardiance®)
NZ615726B2 (en) Dosing regimens for the treatment of fabry disease
NZ715144A (en) Insulin glargine/lixisenatide fixed ratio formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250204